Latest news
Glasgow-based Mironid raises €39.9 million in Series B to advance rare kidney disease treatment - EU-StartupsEU-Startups · Fri, 07 Aug 2026 12:14:34 GMTDXB: Advancing kidney disease therapies with global deals and a diversified, risk-managed approach - TradingViewTradingView · Thu, 06 Aug 2026 22:21:44 GMTScottish kidney disease biotech Mironid raises $46 million to advance rare disease pipeline - The Pharma LetterThe Pharma Letter · Wed, 05 Aug 2026 16:12:39 GMTMironid - Via RitzauVia Ritzau · Wed, 05 Aug 2026 06:00:00 GMTDr. Laith Al-Rabadi Receives 2026 KidneyCure Award to Advance Kidney Disease Research - School of Medicine | University of UtahSchool of Medicine | University of Utah · Mon, 03 Aug 2026 18:55:09 GMTVirta Health Dramatically Reduces Risk of Advanced Kidney Disease by 62% in Landmark, Real-World Study - Business WireBusiness Wire · Tue, 28 Jul 2026 07:00:00 GMTStudy: Casdatifan Demonstrates Durable Tumor Responses in Heavily Pretreated Patients with Advanced Kidney Cancer | Newswise - NewswiseNewswise · Tue, 28 Jul 2026 00:25:00 GMT